免疫相关细胞水平在乳腺癌中的预测及预后价值  

Predictive and prognostic values of immunocytes in breast cancer

作　　者：周文琪[1] 姚广裕[1] 陈路嘉[1] 胡晓磊[1] 叶长生[1] 

机构地区：[1]南方医科大学南方医院乳腺中心,广州市510515

出　　处：《中国肿瘤临床》2016年第21期967-970,共4页Chinese Journal of Clinical Oncology

摘　　要：乳腺癌是女性高发的恶性肿瘤,目前乳腺癌的综合治疗使其死亡率较前明显降低。随着肿瘤免疫学的发展,乳腺癌的免疫治疗或将成为除手术、放化疗、内分泌治疗及靶向治疗外的新的治疗手段。乳腺癌的相关免疫指标对乳腺癌化疗疗效及其预后的影响也是目前研究的热点,其结果将为乳腺癌个体治疗提供新的思路。本文主要就乳腺癌的相关免疫细胞水平的预测及预后价值进行综述。Breast cancer is one of the most commonly diagnosed malignancies among women. Breast cancer mortality was obviously decreased by systemic treatment. In addition to surgery, chemotherapy, radiotherapy, and endocrine and target therapies, immuno- therapy may become a predominant treatment with the development of tumor immunity. The association between immune parame- ters and the efficacy of chemotherapy, as well as breast cancer prognosis, is becoming an important research focus. Relevant results will provide great significance to individual treatment. Overall, this review describes the predictive and prognostic values of immuno- cytes in breast cancer.

关 键 词：乳腺癌 免疫治疗 中性粒/淋巴细胞比值 肿瘤浸润淋巴细胞 免疫细胞 

分 类 号：R737.9[医药卫生—肿瘤]